Search research articles
Contact Us
Filters
Showing results (31-40 of 37) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 37 results.
British Journal of Pharmacology
|
January 1, 1975
Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites
D J Boullin, D G Grahame-Smith, R P Grimes, et al.
British Journal of Clinical Pharmacology
|
February 1, 1975
Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine
D J Boullin, H F Woods, R P Grimes, et al.
British Journal of Clinical Pharmacology
|
February 1, 1975
Resuspension of platelets: enhanced 5-hydroxytryptamine-induced aggregation in chlorpromazine treated patients due to changes in platelet properties
D J Boullin, D G Grahame-Smith, R P Grimes, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
July 1, 1975
Responses of isolated human basilar arteries to 5-hydroxytryptamine, noradrenaline, serum, platelets, and erythrocytes
L M Starling, D J Boullin, D G Grahame-Smith, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
July 1, 1979
Relationship between presence of vasoconstrictor activity in cerebrospinal fluid and time after subarachnoid haemorrhage from rupture of cerebral arterial aneurysms
T M Hunt, G H Du Boulay, W P Blaso, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 1, 1983
The 5-hydroxytryptamine antagonist ketanserin inhibits the vasoconstrictor activity of per-operative CSF, from subarachnoid haemorrhage patients, on isolated tissues
P C Tagari, A H Kaye, P J Teddy, et al.
Journal of Neurosurgery
|
May 1, 1984
CSF smooth-muscle constrictor activity associated with cerebral vasospasm and mortality in SAH patients
A H Kaye, P C Tagari, P J Teddy, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 37) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 37 results.
British Journal of Pharmacology
|
January 1, 1975
Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites
D J Boullin, D G Grahame-Smith, R P Grimes, et al.
British Journal of Clinical Pharmacology
|
February 1, 1975
Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine
D J Boullin, H F Woods, R P Grimes, et al.
British Journal of Clinical Pharmacology
|
February 1, 1975
Resuspension of platelets: enhanced 5-hydroxytryptamine-induced aggregation in chlorpromazine treated patients due to changes in platelet properties
D J Boullin, D G Grahame-Smith, R P Grimes, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
July 1, 1975
Responses of isolated human basilar arteries to 5-hydroxytryptamine, noradrenaline, serum, platelets, and erythrocytes
L M Starling, D J Boullin, D G Grahame-Smith, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
July 1, 1979
Relationship between presence of vasoconstrictor activity in cerebrospinal fluid and time after subarachnoid haemorrhage from rupture of cerebral arterial aneurysms
T M Hunt, G H Du Boulay, W P Blaso, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 1, 1983
The 5-hydroxytryptamine antagonist ketanserin inhibits the vasoconstrictor activity of per-operative CSF, from subarachnoid haemorrhage patients, on isolated tissues
P C Tagari, A H Kaye, P J Teddy, et al.
Journal of Neurosurgery
|
May 1, 1984
CSF smooth-muscle constrictor activity associated with cerebral vasospasm and mortality in SAH patients
A H Kaye, P C Tagari, P J Teddy, et al.
Page
of 4